Phase II Trial Opens: Yinqiaosan-Maxingganshitang vs Placebo in Mild-to-Moderate COVID-19 — Telemedicine-Delivered TCM Under Rigorous RCT Scrutiny
247 Health News Editorial
·31 July 2026
·5 min read
·clinical-trialsA Phase II randomised controlled trial from the Chinese University of Hong Kong is rigorously evaluating Yinqiaosan-Maxingganshitang — a classical TCM herbal compound — against placebo in adults with mild to moderate COVID-19, delivered entirely via telemedicine. With enrolment open and a primary endpoint of time to defervescence, this trial could generate the first high-quality placebo-controlled evidence for a widely used but incompletely validated traditional therapy. Clinicians in infectious diseases, respiratory medicine, and integrative health should follow its progress closely.
Originally reported by ClinicalTrials.gov
References
- 1.Chinese University of Hong Kong. (2023). Assessing the efficacy and safety of Yinqiaosan-Maxingganshitang in the treatment of the major symptoms of mild and moderate COVID-19 by telemedicine — a randomized, double-blind, placebo-controlled trial (NCT05787327). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT05787327
- 2.Luo, H., Tang, Q. L., Shang, Y. X., Liang, S. B., Yang, M., Robinson, N., & Liu, J. P. (2020). Can Chinese medicine be used for prevention of corona virus disease 2019 (COVID-19)? A review of historical classics, research evidence and current prevention programs. Chinese Journal of Integrative Medicine, 26(4), 243–250. https://doi.org/10.1007/s11655-020-3192-6
- 3.Ang, L., Song, E., Lee, H. W., & Lee, M. S. (2020). Herbal medicine for the treatment of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis of randomized controlled trials. Journal of Clinical Medicine, 9(5), 1583. https://doi.org/10.3390/jcm9051583
- 4.Hammond, J., Leister-Tebbe, H., Gardner, A., Abreu, P., Bao, W., Wisemandle, W., Baniecki, M., Hendrick, V. M., Damle, B., Simón-Campos, A., Pypstra, R., & Rusnak, J. M. (2022). Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine, 386(15), 1397–1408. https://doi.org/10.1056/NEJMoa2118542
- 5.Zhang, X., Li, Y., Wang, Y., Zhang, Y., Hou, Y., Zhao, Y., & Li, X. (2021). Effectiveness of Yinqiaosan and its related preparations in the treatment of influenza: A systematic review and meta-analysis. Phytomedicine, 90, 153609. https://doi.org/10.1016/j.phymed.2021.153609
- 6.National Institutes of Health. (2024). Coronavirus disease 2019 (COVID-19) treatment guidelines. https://www.covid19treatmentguidelines.nih.gov/
2
247 Health News Editorial
247 Health News is a medical intelligence platform delivering evidence-based research appraisals, clinical trial monitoring, and health technology news for healthcare professionals.
Related Articles
clinical-trials
Digital Health Platform vs Case Manager Support in Hypertension Management: Taiwan's 1,726-Participant Trial Signals a Shift in Blood Pressure Care Delivery
3 Aug 2026
clinical-trials
Phase II Trial: AI-Powered Wysa Chatbot vs Unmet Need — Digital Eating Disorder Prevention in At-Risk Adolescents
3 Aug 2026
clinical-trials
Pilot Trial Targets the Inpatient-to-Outpatient Gap: Digital Smoking Cessation Intervention for Persons With Serious Mental Illness — Key Findings for Clinicians
3 Aug 2026
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service